The Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute have partnered to form the ADDF-Harrington Scholar Award. This grant is designed to accelerate the translation of academic discoveries into medicines for treating, preventing, or curing patients with Alzheimer's disease and related dementias. Of particular interest for the 2022 call are targets related to neurovascular health and epigenetics. Researchers working on drug development programs that are relevant to, but not presently focused on, the Alzheimer's field are encouraged to apply.

FREQUENTLY ASKED QUESTIONS

QUESTION	RESPONSE
What diseases are eligible for this grant award?	Novel treatment approaches to treat Alzheimer's disease and related dementias. Of particular interest for the 2022 call are targets related to neurovascular health and epigenetics.
Does the PI need to be working on Alzheimer's disease?	No. Researchers working on drug development programs that are relevant to, but not presently focused on, the Alzheimer's field are strongly encouraged to apply.
What is the grant award amount?	Up to \$600,000 for two years.
How is this award different from other drug development grant awards?	Award recipients receive personalized discovery and development support from Harrington Discovery Institute's Therapeutics Development team of advisors, who are pharma-experienced industry leaders with significant experience bringing drugs to market. The award recipient also receives dedicated project management support.
How many projects will you fund?	We fund up to 3 projects annually.
What is the grant period and what is the expected start date?	Each class of awardees will receive funding and support for two years. Projects for the 2022 class of scholars are expected to commence during the 1 st quarter of 2023.

We typically fund projects between lead optimization and IND-enabling work. We like to see that the applicant has identified lead agents that will serve as a clear starting point for the greatest impact from our Therapeutics Development team.
Any therapeutics modality is eligible.
The grant funds small molecule, biologic and gene therapy projects. Device projects and biomarker development projects are <u>not</u> eligible for funding.
Yes, if there is new IP or potential novel IP associated with the indication.
The PI must hold a faculty position at an accredited academic medical center, university or research institution in the US, Canada or UK, and conduct the majority of the research at that institution. Post-doctoral fellows are <u>not</u> eligible to apply as PI.
No. Applicants with an MD or PhD degrees are urged to apply.
Yes, but only one applicant/Principal Investigator is recognized as the Harrington Scholar. This person will have responsibility for project oversight and financial management.
No. We can only support projects in which the asset and ensuing intellectual property (IP) are under full control of the PI or their institution.
No. IP rights are retained by the PI or their institution.
When the project is ready for commercial partnership, Harrington Discovery Institute will facilitate introductions between commercial partners and the PI.

What type of costs can the award funds be applied to?	 GRANT FUNDS ARE PROVIDED BY THE ADDF. ALLOWABLE AND UNALLOWABLE COSTS ARE AS FOLLOWS: The ADDF's mission is to accelerate discovery of a novel treatment for Alzheimer's disease and other related dementias. The ADDF seeks to fulfill its mission by providing funding for drug discovery and development projects. As a public charity, the ADDF's funding must be used specifically for an approved scientific project that advances the ADDF's stated mission. ADDF funding may be provided for approved personnel costs, supplies (<i>e.g.</i>, consumables, chemicals, animals), small non-durable equipment up to \$2,500, consultants, and patient costs related to clinical trials. ADDF funding is not provided for indirect costs/overhead, capital equipment, equipment service contracts, publication costs, or travel (unless travel is pre-approved under special circumstances).
Can salary for other faculty members that are assisting in the project, such as junior faculty and clinical doctors, be covered?	Yes, the award may be used to cover salaries for post-doctoral fellows (or junior faculty or clinical doctors) equivalent to the percentage of effort devoted to the project.
Is it an issue if the PI is receiving grant funding from other sources?	No, but there can be no overlap between the funding sources and the proposed project.
Will the information I send in my proposal be kept confidential?	Yes. All information received by ADDF and Harrington Discovery Institute is considered confidential. If the applicant is concerned about some aspect of the review process, they may contact us at <u>Questions@HarringtonDiscovery.org</u> .
Is a Letter of Intent (LOI) required for this application?	Yes. The Letter of Intent is due July 18, 2022.
Can one PI submit multiple proposals for consideration?	Yes.
Is there any limit to the number of applications one university can submit?	No.

Г

Can I re-submit a previously submitted letter of intent, or full proposal?	Yes. We accept letters of intent, or full proposals, that have been previously submitted. If you are reapplying, we ask that you include a response to reviewer comments and progress from the last cycle.
Am I eligible to apply, even if I previously was awarded funds from Harrington or ADDF?	Yes. Past recipients of Harrington or ADDF awards may submit <u>new</u> <u>and distinct</u> proposals. Recipients may not seek additional support for previously funded projects.
How long until there is a decision on my grant application?	The call for letters of intent opens June 1 , 2022 and closes July 18 , 2022 . The full proposal deadline is October 24 , 2022 for those invited to submit a full proposal. Award recipients will be selected and notified in April 2023 .

For questions on submitting an application, please contact us at: <u>grants@alzdiscovery.org</u> or <u>Questions@HarringtonDiscovery.org</u>.

For scientific inquiries, please contact Meriel Owen, PhD, Associate Director of Scientific Affairs, ADDF: <u>mowen@alzdiscovery.org</u>.